Connect with us

Cannabis News

120 Pharmacies in Georgia Applied to Sell Medical Cannabis, The DEA Says Hold My Beer and Shuts It Down

Published

on


Georgia pharamacies sell medical marijuana

Little Five Points Pharmacy, situated in Atlanta, is among the nearly 120 independent pharmacies in Georgia that recently sought approval to distribute medical marijuana through a new state initiative. However, last week, the Drug Enforcement Administration (DEA) issued a warning to Little Five Points Pharmacy and other pharmacies statewide, asserting that such activities are illegal due to THC being categorized as a Schedule I controlled substance.

 

Expressing his dismay, Ira Katz, a pharmacist at Little Five Points Pharmacy, conveyed his disappointment, stating, “We always felt, as pharmacists, that this is a drug and it should be kept in the pharmacy. It should be regulated by the pharmacy. So we are very disappointed that the DEA is choosing to keep it out of the pharmacy, where it belongs.”

 

Katz, elaborating further in discussions with Atlanta First News, emphasized the significance of the issue, saying, “Because who better than your independent pharmacy, who knows your history and knows your medical history, can best dispense medical marijuana?”

 

Highlighting the potential benefits, Katz added, “For chronic pain, we believe that if we can get patients off these high doses of opioids, the hydrocodone, the oxycodone, the combinations of these things, then through the use of medical cannabis, we believe we can help contribute to slowing down this opiate crisis.”

 

In response to the DEA’s letters, Todd Heydel of Peachtree NORML criticized them as “ridiculous” and expressed frustration, stating in comments to Atlanta First, “We have children that are sick, that need medicine and need safe, legal access. And in Georgia, it seems like every time we try to take a step forward, there’s pushback.”

 

Supporters of Georgia’s medical marijuana system, including Michael Mumpter of Georgians for Responsible Marijuana Policy, have embraced the federal warning letter.

 

Mumpter expressed his expectation that, in the immediate future, pharmacies engaged in dispensing medical marijuana may need to halt their operations or face potential conflicts with the DEA, stating, “I imagine, in the short term, the pharmacies who started dispensing medical marijuana would have to stop or risk confrontation with the DEA,” in an interview with 11 Alive.

 

As of now, Georgia’s political figures and regulators have maintained a silence regarding the DEA’s warning. Several members of Georgia’s U.S. House delegation did not respond to requests for comments from Marijuana Moment this week. On the Senate side, there was no response from Sen. Raphael Warnock’s staff, despite his recent advocacy for social equity in marijuana reform during a committee hearing. Sen. Jon Ossoff’s office declined to provide a comment.

 

Requests for comments from Georgia’s Board of Pharmacy and Department of Public Health also went unanswered.

 

The DEA’s advisory could face complications due to a congressional budget rider that prohibits the Department of Justice from allocating resources to interfere with the implementation of state medical marijuana laws. Initially enacted in 2014, this provision was recently extended until at least February 2024. The potential violation of this provision by the DEA’s warning or enforcement actions remains unclear, with some advocates suggesting that the mere expenditure on postage for the letters could be considered a resource expenditure interfering with Georgia’s state-legal medical marijuana system.

 

Georgia’s Board of Pharmacy initiated the acceptance of applications from independent pharmacies to dispense low-THC cannabis oil, limited to 5% THC under state law, in October. The objective was to enhance medical marijuana access for patients, who were previously limited to just seven dispensaries established in the state since April.

 

According to an early report from The Atlanta Journal-Constitution in the same month, almost 120 pharmacies had applied to the Board of Pharmacy to distribute marijuana products from Botanical Sciences, one of the state’s licensed producers. Pharmacies were also authorized to dispense medical cannabis from Trulieve, the state’s other licensed producer.

 

Botanical Sciences’ Products Gain Traction in Georgia Pharmacies

 

By late October, at least three pharmacies had initiated the distribution of Botanical Sciences products, as highlighted in a company press release. The company’s website map indicates plans for over 100 additional pharmacies to open soon.

 

An Associated Press report suggests that if the sales of medical cannabis products were extended to all these locations, approximately 90% of Georgians would have access to a pharmacy selling marijuana within a 30-minute drive. It’s essential to note that the state’s authorization is limited to independent pharmacies and does not encompass larger chains like CVS and others.

 

The DEA issued warning letters to Georgia pharmacies during its ongoing assessment of a recommendation by the Department of Health and Human Services (HHS) proposing the rescheduling of marijuana under the Controlled Substances Act (CSA), potentially to Schedule III. The leak of this recommendation occurred in late August, and as of now, the DEA has not made a public response.

 

Although the Congressional Research Service (CRS) recently inferred that the DEA would likely adhere to the HHS recommendation based on historical precedent, it’s crucial to acknowledge that the DEA retains the authority to disregard the health agency’s guidance, as it holds final jurisdiction over the Controlled Substances Act (CSA).

 

HHS Documents Shed Light on Marijuana Rescheduling Considerations

 

In October, the Department of Health and Human Services (HHS) initially disclosed a redacted one-page version of the rescheduling memo. Subsequently, during the past week, the government released an additional 252-page set of documents about the review, with a majority of the information obscured.

 

Broadly, the new documents delineate recent scientific findings that have emerged since the previous denial of a rescheduling petition. HHS suggests that these developments may warrant reconsideration for the rescheduling of marijuana.

 

“The current review is largely focused on modern scientific considerations regarding whether marijuana has a currently accepted medical use (CAMU) and on new epidemiological data related to marijuana abuse since the 2015 HHS evaluation of marijuana under the Controlled Substances Act’s eight-factor analysis.”

 

HHS acknowledges that it has extensively analyzed data concerning the abuse potential of marijuana but underscores the complexity of this assessment, stating, “no single test or assessment provides a complete characterization.”

 

Earlier this month, six Democratic governors penned a letter to the Biden administration, urging the completion of the rescheduling process by the year’s end. The letter suggests that if marijuana is moved to Schedule III, pharmacies, as implied in the DEA’s letter to the Georgia pharmacy, would be authorized to dispense marijuana. However, pharmaceutical products would first need approval from the Food and Drug Administration.

 

The governor’s letter emphasizes that rescheduling cannabis aligns with ensuring a safe and regulated product that Americans can trust. Citing a poll indicating that 88 % of Americans support legalization for medical or recreational use, the letter underscores the consensus that while there may be differing opinions on recreational cannabis legalization, the cannabis industry is here to stay. The governors emphasize the importance of supporting state-regulated markets for the safety of the American people.

 

Bottom Line

 

Amid the DEA’s warning to Georgia’s independent pharmacies, epitomized by Little Five Points Pharmacy, the clash between regulatory constraints and the vision for localized healthcare provision is palpable. Pharmacist Ira Katz’s disappointment underscores this tension, while political figures’ silence and potential legal complications add an air of uncertainty to the state’s medical marijuana landscape. Simultaneously, the growing popularity of Botanical Sciences’ products indicates a rising demand, albeit with challenges in achieving widespread accessibility. The ongoing evaluation of marijuana rescheduling by the HHS, coupled with governors advocating urgency, signals a broader national conversation. Georgia stands at a pivotal moment, where the intersection of healthcare, regulation, and public sentiment will shape the future of medical marijuana access, leaving key questions unanswered.

 

GEORGIA SELLING WEED, READ ON…

GEROGIA WANTS TO SELL MEDICLA MARIJUANA

GEORGIA WANTS PHARMACIES TO SELL MEDICAL MARIJUANA OIL?



Source link

Cannabis News

What if the World’s Biggest Tobacco Company Entered the Cannabis Industry?

Published

on

By


philip morris marijuana

The World’s Biggest Tobacco Company Is Quietly Entering The Weed Industry

What Does This Mean For The Future Of Weed?

 

From the 1950’s to the 1990’s, cigarettes were considered to be a ‘cool’ habit and somewhat of a fashion accessory globally.

 

There was even a time when Hollywood celebrities were photographed smoking, which made them seem like the epitome of sophistication. Big names including Humphrey Bogart and James Dean were pictured smoking, but it was also so common and accepted around the world. That did not last long, as eventually evidence that cigarettes killed people from cancer and other fatal health conditions became impossible to ignore.


While there were many names in Big Tobacco that helped popularize the consumption of cigarettes, and made it easy for people to get access to it, Philip Morris International (PMI) were one of the biggest players – and they still are, to this day. They own some of the most common cigarette brands that are consumed around the world, including Marlboro, Chesterfield, and L&M. Surely, one can blame PMI’s products for tempting people to make poor health choices that may have taken them to the grave…

 

According to the World Health Organization, tobacco smoking is responsible for the deaths of around 8 million people globally.


Yet, with the rise of cannabis, PMI wanted a piece of the pie.

 

The History Of Philip Morris’ Interests In Cannabis


If you’re only hearing about Big Tobacco’s interest in cannabis right now, you might be shocked to learn that their interest in weed goes as far back as 1969. There are some internal documents that prove PMI was interested in learning about the potential of cannabis. However, they were considering weed a competitor as well as a potential product.

In fact, a 1970 memo even shows that PMI acknowledges the possibility of marijuana legalization.


Fast forward to 2016, when PMI made a significant investment worth $20 million to an Israeli biotech firm specializing in medical cannabis, called Syqe Medical. At the time, Syqe was working on developing a medical marijuana inhaler which would provide metered dosing of weed for medical patients. According to the deal, Syqe Medical will also work on developing certain technologies that would enable Philip Morris to minimize the health effects caused by smoking.

 

By 2023, Philip Morris made a deal to acquire Syqe Medical for a cool $650 million, as long as there were certain conditions met. In a report by Calcalist, the deal features a number of milestones, though the bottom line is that if the inhaler developed by Syqe passes the clinical trials, PMI will then go ahead to buy all shares of the company for the aforementioned amount.

 

Another Silent Move Into The Weed Space

 

More recently, in January 2025, a press release was published detailing Vectura Fertin Pharma’s (VFP), a subsidiary of Philip Morris International, joint venture with a Canadian biotech firm focusing on cannabinoid-based drugs – Avicanna.

 

According to the press release, the joint venture seeks to promote cannabis accessibility and research. Avicanna already has a stronghold in the wellness sector. However, the press release hardly makes any other mention about the involvement of Philip Morris International, but it’s clear that Big Tobacco has long had their eye in the cannabis industry. Back in 2016, when they first got involved with Syqe Medical, it highlighted the firm’s interest in wellness, but the partnership with Avicanna cements that.

 

Changes In Consumer Perception And Habits

 

It only makes sense for Big Tobacco to pivot to cannabis – or wellness, in general. After all, if you can’t beat em, join em!


And it’s clear: for several years now, there has been a decrease in cigarette smoking; young adults are now shifting from tobacco, as well as alcohol, and increasing their cannabis consumption instead.

 

And Philip Morris isn’t the only player in Big Tobacco who’s expressed an interest in a slice of the (weed) pie. Back in 2017, American holding company Altria Group began moving away from cigarettes, with their $1.8 billion investment into the Cronos Group, a large Canadian cannabis company. Altria owns several big American companies including Philip Morris; so much so, that even their website now declares the tagline: “Moving Beyond Smoking”.

 

However, Altria faced issues due to regulatory concerns.

 

British American Tobacco (BAT) has also been interested in cannabis. For some time now, they’ve been researching weed products, particularly infusing CBD and THC into their electronic cigarettes which are sold under the Vuse and Vype brand names. In 2021, BAT began a trial launch of CBD products in the United Kingdom.


RJ Reynolds, which is also now under British American Tobacco, has also considered joining the weed industry. According to internal documents, RJ Reynolds has considered cannabis both an opportunity and a competitor as far back as the 1970s.

 

Conclusion


At the end of the day, cannabis isn’t a real threat to the tobacco industry. The tobacco industry simply shot itself on the foot – all it needed was time, to prove that it does indeed cause cancer and kill people. On the other hand, cannabis was a friend more than a foe: legalization and a growing consumption of weed proved its ability to save lives.

 

That said, the relationship between tobacco and weed continues to evolve. Through cannabis legalization, Big Tobacco can learn from the challenges and opportunities that cannabis had to go through. It can be said that one thing is clear, though: the drop in tobacco consumption is a major opportunity for cannabis, with more people looking to substitute tobacco with a healthier alternative.

As a response, we may continue to see tobacco companies investing in Big Cannabis – just as we’ve seen in the examples mentioned above. This partnership is fantastic news for both industries, and we can only hope to see more!  

 

PHILIP MORRIS’ MOVES IN CANNABIS, READ ON…

PHILIP MORRIS BUYS MEDICAL MARIJUANA INHALER

WHY DID PHILIP MORRIS JUST BUY A MEDICAL MARIJUANA INHALER COMPANY?



Source link

Continue Reading

Cannabis News

Who are the Next 5 States to Legalize Recreational or Medical Cannabis Starting in 2025?

Published

on

By


next states to legalize

As the landscape of marijuana legalization continues to evolve across the United States, 2025 is shaping up to be a pivotal year for states considering reforms. Advocacy groups are closely monitoring legislative developments and public sentiment, identifying specific states that are likely to make significant strides toward legalization. This article explores the states most likely to legalize marijuana in 2025, examining the political climate, public opinion, and advocacy efforts that may influence these changes.

 

The Current State of Marijuana Legalization in the U.S.

 

As of 2023, a growing number of states have legalized marijuana for both medical and recreational use. According to the National Conference of State Legislatures (NCSL), 21 states and Washington D.C. have legalized recreational marijuana, while 37 states allow medical marijuana use. This rapid expansion reflects changing public attitudes toward cannabis, which have shifted dramatically over the past two decades.

 

Public Opinion Trends

 

Public support for marijuana legalization has reached unprecedented levels. A Gallup poll conducted in late 2022 found that 68% of Americans support legalizing marijuana, a significant increase from just 25% in 1995. This shift in public opinion is crucial for lawmakers as they consider new legislation. Advocacy groups are leveraging this support to push for reforms in states where legalization has yet to occur.

 

 The Role of Advocacy Groups

 

Organizations such as the National Organization for the Reform of Marijuana Laws (NORML) and the Marijuana Policy Project (MPP) play a vital role in advocating for legalization. They provide research, mobilize grassroots campaigns, and lobby lawmakers to promote cannabis reform. Their insights into which states are most likely to legalize in 2025 are based on legislative trends, political dynamics, and public sentiment.

 

Key States Likely to Legalize Marijuana in 2025

 

Pennsylvania has emerged as a strong contender for marijuana legalization in 2025. The state has a robust medical marijuana program established in 2016 that has seen significant success, with over 600,000 registered patients. However, advocates argue that the time has come to expand access to adult-use cannabis.

 

Political Support

 

The recent election of Governor Josh Shapiro has energized legalization efforts. Shapiro has expressed support for legalizing recreational marijuana and has indicated a willingness to work with lawmakers across party lines. In early 2025, a bipartisan bill is expected to be introduced that aims to create a regulated market for adult-use cannabis.

 

 Advocacy Efforts

 

Advocacy groups are actively mobilizing support among residents and lawmakers alike. Campaigns highlighting the potential economic benefits—such as job creation and tax revenue—are gaining traction. Additionally, public polls indicate strong support among Pennsylvanians for legalization, further bolstering advocacy efforts.

 

Hawaii has long been known for its progressive stance on cannabis; it was one of the first states to legalize medical marijuana in 2000. However, efforts to legalize recreational use have stalled in previous legislative sessions.

 

 Current Developments

 

In 2025, advocates are optimistic about renewed efforts to pass comprehensive cannabis legislation. The Senate previously approved a bill aimed at legalizing recreational use, but it failed in the House due to opposition from conservative lawmakers.

 

 Political Dynamics

The political landscape appears more favorable this year with new leadership in the House that may be more open to discussing cannabis reform. Governor Josh Green has also expressed support for legalization, emphasizing its potential economic benefits for Hawaii’s tourism-driven economy.

 

 Advocacy Strategies

 

Advocacy groups are focusing on grassroots campaigns and community engagement to build momentum for legalization. Public forums and educational events aim to inform residents about the benefits of legalization while addressing concerns regarding regulation and safety.

 

South Carolina has made strides toward medical marijuana legalization but remains one of the few states without comprehensive access to cannabis products. In recent years, lawmakers have introduced several bills aimed at establishing a medical program; however, these efforts have faced significant hurdles.

 

 Legislative Prospects for 2025

 

In 2025, advocates are hopeful that a revived medical marijuana proposal will gain traction. The proposed legislation would allow patients with qualifying conditions access through licensed pharmacies under strict regulations.

 

 Political Climate

 

The political climate remains challenging, with resistance from conservative factions within the legislature. However, increasing public support—evidenced by recent polls showing over 70% approval for medical cannabis—may sway some lawmakers toward supporting reform.

 

 Advocacy Efforts

 

Advocacy organizations like SC Compassionate Care are working tirelessly to educate the public and legislators about the benefits of medical marijuana. They emphasize patient stories and health outcomes as part of their strategy to garner support.

 

Kansas is one of the few remaining states without any form of legalized marijuana use. Despite this restrictive environment, there is a growing movement advocating for medical cannabis legislation.

 

 Legislative Opportunities

 

In 2025, advocates believe there is a significant opportunity for progress on medical marijuana legislation. Several bills have been introduced in previous sessions that gained some bipartisan support but ultimately failed due to opposition from key lawmakers.

 

 Public Sentiment

 

Public opinion in Kansas is shifting; recent surveys indicate that nearly 60% of residents support legalizing medical marijuana. This growing acceptance may influence legislators who have previously opposed reform.

 

 Advocacy Strategies

 

Groups like Kansas Cannabis Coalition are actively campaigning for change by organizing rallies and educational events throughout the state. They aim to raise awareness about the therapeutic benefits of cannabis while pushing for legislative action.

 

North Carolina has been making headlines regarding potential cannabis reform. While it currently allows limited use of CBD oil for certain medical conditions, comprehensive medical or recreational legalization remains elusive.

 

 Political Dynamics

 

In recent years, there have been increased discussions among lawmakers about introducing medical marijuana legislation. The current governor supports reform efforts; however, opposition from conservative members poses challenges.

 

 Advocacy Efforts

 

Advocacy groups such as NC NORML are working diligently to build grassroots support for legalization initiatives. They focus on educating citizens about cannabis benefits while lobbying legislators directly.

 

Wisconsin’s approach toward cannabis remains conservative compared to neighboring states like Illinois and Michigan. While some local municipalities have decriminalized possession or implemented medicinal programs at their discretion, comprehensive statewide reform is still lacking.

 

 Legislative Prospects

Advocates believe that changing political dynamics could lead Wisconsin toward more progressive policies regarding both medical and adult-use legalization by 2025. Recent elections have resulted in a more favorable balance within state government regarding cannabis issues.

 

Public Support

 

Public opinion polls indicate strong support among Wisconsinites—over 60% favoring legalization efforts—creating an opportunity for advocates seeking legislative change.

 

Advocacy Strategies

 

Organizations like Wisconsin NORML are mobilizing citizens through educational campaigns aimed at dispelling myths surrounding cannabis while promoting its economic benefits through taxation and job creation associated with regulated markets.

 

New Hampshire has long been considered an outlier among New England states regarding cannabis laws; it legalized medical marijuana back in 2013 but has yet to pass adult-use legislation despite numerous attempts over recent years.

 

Current Developments

 

In early 2025, advocates anticipate renewed efforts aimed at legalizing recreational use through proposed bills introduced during legislative sessions scheduled throughout spring months ahead.

 

 Political Climate

 

While there is bipartisan interest among some legislators regarding potential reforms related specifically towards taxation structures associated with regulated markets—opposition remains strong from conservative factions within government bodies overall limiting chances significantly unless public pressure mounts significantly enough leading into future elections cycles ahead!

 

Virginia made headlines when it legalized recreational cannabis possession starting July 1st ,2021—but sales remain unregulated until further action occurs within state government bodies responsible overseeing these matters moving forward!

 

Legislative Prospects

 

Advocates believe that enhancing existing laws by adding regulated sales will be crucial steps towards creating an effective market structure benefiting consumers while generating tax revenue needed fund essential services statewide!

 

 Conclusion

 

As we look ahead into 2025—the landscape surrounding marijuana legalization continues evolving rapidly across various states nationwide! With growing public support coupled alongside advocacy group efforts pushing forward reforms—it’s clear many opportunities exist within multiple jurisdictions ripe opportunities await those willing engage actively participate shaping future policies governing this vital industry.

 

WHAT STATES MAY NEVER LEGALIZE WEED, READ ON…

STATES TO NEVER LEGALIZE WEED

WHAT STATES MAY NEVER LEGALIZE WEED, HERE ARE 4 IDEAS!



Source link

Continue Reading

Cannabis News

Emotional Regulation Get Easier with Cannabis?

Published

on

By


emotional regulation with cannabis

Emotional regulation refers to an individual’s ability to manage to various emotional stimuli in an appropriate manner.

When one is able to regulate their emotions, it means that they are able to withhold intense and extreme emotions, even when the situation normally calls for it. As a result, they are able to express their emotions in a proper way; it is controlled but not suppressed, it’s mindful and aware. Effective emotional regulation has been linked to emotional maturity, better relationships, and an improvement in overall well-being.


However, using certain drugs as well as alcohol have proven to negatively impact one’s ability to regulate their emotions. This is because drugs engage with the neurotransmitters in the brain, including those responsible for the production of serotonin and dopamine, which are necessary for healthy emotional regulation. When we consume central nervous system depressants such as alcohol, as well as stimulants in drugs, these severely impede our serotonin levels which can cause depression and other mental health issues. In addition, drugs have been found to affect emotional dysregulation and dependence.


But not cannabis.

 

According to the results of a clinical study conducted by researchers at the Oregon State University and Washington State University, inhaling weed containing over 20% THC was not found to have any impact on emotional regulation.

For the study, investigators analyzed the effects of weed smoking on 12 adults; all the participants already had experience smoking weed in the past and even used their own cannabis supply. The researchers then analyzed the mood and emotional regulation capabilities of the participants during times of sobriety as well as when they were stoned from weed. Surprisingly, they found that the subjects’ performance didn’t differ when made to undergo several tasks after smoking weed.


“There was no evidence that acute high-potency cannabis use affected participants’ implicit or explicit emotional regulation,” they said. The researchers also noted that the participants acknowledged there was an improvement in their mood and anxiety reduction after using weed.


“The current pilot study assessed whether being under the influence of high-potency cannabis flower affects emotion regulation among a sample of young adults who use cannabis regularly,” they concluded. “While participants reported more positive mood and decreases in anxiety while intoxicated, there was no evidence to suggest that intoxication from high-potency cannabis flower affected emotion regulation,” the researchers wrote.

 

How Else Can Cannabis Benefit Emotional Health?

 

Thousands of people rely on cannabis for its benefits on their emotional and mental well-being. In fact, most cannabis consumers have a positive association with cannabis and emotions, since it can effectively help them reduce encounters of negative emotions in general. For example, instead of ruminating in stress and worry, people can medicate with weed at the end of the day. This not only aids in relaxation, but also offers a natural, safe outlet for coping with the stresses of everyday life.


In the same vein, this is also why more individuals, particularly those in high-stress positions such as parents, CEO’s, and entrepreneurs, have made microdosing or getting high a part of their daily life. No longer is alcohol seen as the only way to cope: weed is in, and it’s a much healthier way of dealing with life.

 

While this may be something that science can’t explain just yet, cannabis does have the unique ability to slow down one’s racing thoughts and the endless mental chatter, while helping make it easier to focus on the present. For this reason and more, weed has already been widely integrated into many wellness retreats in legal cities. Weed, mindfulness, and yoga simply go together so well, enhancing the peaceful effects of one another. Cannabis consumers can also enjoy a great deal of relaxing activities with a heightened sense of enjoyment, effectively helping one forget about their negative emotions such as anger, stress, and frustration.

So the next time you’re feeling extremely irritable or pissed off, why not pop a gummy or have a toke, and spend some time outside. You’ll see how difficult it can be to stay mad.

 

What You Take Matters

 

For those who want to use cannabis to improve their emotional regulation, what you take – and how much of it – matters just as much too.


That’s why there are many more studies suggesting that low-dose THC is best especially for anxiety and stress. On the other hand, high doses of THC can be detrimental for your mental and emotional well-being.

 

According to a 2017 study conducted by researchers at the University of Illinois at Chicago and the University of Chicago: “We found that THC at low doses reduced stress, while higher doses had the opposite effect, underscoring the importance of dose when it comes to THC and its effects,” they said. The same is also true for psychedelics, which can partly explain the popularity of microdosing psychedelics. Meanwhile, anything that can you too high can in fact, cause intense anxiety and stress.

 

Conclusion


It can feel almost impossible to avoid stressful situations that can cause you to feel out of whack, emotionally. In fact, stress is just a normal part of life. But losing your temper, ruminating in negative emotions for hours, and being so upset that it affects other aspects of your life, is not normal.


That said, there are a variety of ways you can deal with stress and the negative emotions it brings. Cannabis can be a key ingredient for helping you restore balance in your emotions as well as mental health.

 

CANNABIS AND EMOTIONAL HOMEOSTATIS, READ ON…

MARIJUANA AND EMOTIONAL HOMOSTATIS

CANNABIS FOR EMOTIONAL HOMESTATIS – WHAT WE NOW KNOW!

 



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media